Exclusive Online Content
WACKER & CordenPharma Develop Solutions for Formulating Lipid Nanoparticles, Expanding Their Portfolio for Advanced Medicines
WACKER and CordenPharma have signed a development partnership in the field of Lipid Nanoparticle formulation. The two companies announced they plan to jointly develop know-how…
Immatics & Bristol Myers Squibb Enter Global Exclusive License for TCR Bispecific Program IMA401
Immatics N.V. and Bristol Myers Squibb recently announced they have entered into a license, development, and commercialization agreement for Immatics’ TCR Bispecific candidate, IMA401…..
TheraPanacea & Biogen Announce New Collaboration With the Potential to Advance Digital Health for Personalized Medicine in Neuroscience
Biogen Inc. and TheraPanacea recently announced they have entered into a collaboration focused on multiple therapeutic areas in neuroscience, to further build on the companies’ existing relationship…..
HiberCell to Collaborate With Merck on Phase 2 Clinical Trial of Odetiglucan in Combination With KEYTRUDA in Patients With Metastatic Breast Cancer
HiberCell recently announced a clinical trial collaboration with Merck. This metastatic breast cancer clinical trial evaluates KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with….
Vaccitech Acquires Avidea Technologies to Expand Product Pipeline & Strengthen Scientific Leadership in Immunotherapies & Vaccines
Vaccitech plc recently announced that it has acquired US-based Avidea Technologies, Inc. The consideration to Avidea’s existing shareholders is $40 million….
Pfizer to Acquire Arena Pharmaceuticals for $6.7 Billion
Pfizer Inc. and Arena Pharmaceuticals, Inc. recently announced the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical-stage company developing….
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
Precision BioSciences, Inc. recently announced program updates across its allogeneic CAR T cell therapy pipeline, including updated data for its Phase 1/2a clinical study of PBCAR0191 with enhanced lymphodepletion (eLD) presented at….
Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination With Pembrolizumab in Metastatic Breast Cancer
Intensity Therapeutics, Inc. recently reported safety, pharmacokinetic, biomarker, and efficacy data using INT230-6, with and without pembrolizumab, in heavily pretreated refractory breast cancer patients as part of the….
Fareva & ApiJect Sign Licensing Agreement to Create a France-Based 500-Million Unit Annual Capacity for Single-Dose Prefilled Vaccine Injections
Fareva and ApiJect Systems, Corp. recently announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and….
BrainStorm Cell Therapeutics & Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing
BrainStorm Cell Therapeutics Inc. and Catalent recently announced that the technology transfer for NurOwn manufacturing at Catalent’s facility has been finalized….
EXCLUSIVE ONLINE CONTENT
Bespak & H&T Presspart Enter Collaboration Agreement to Advance Transition to Low GWP Propellants in pMDIs
Partnership will provide GMP filling capabilities and development support for clinical trial programs with low GWP propellants….
PCI Pharma Services Begins Installation of Sterile Fill-Finish & Lyophilization Line as Part of $100-M New Facility Expansion
PCI Pharma Services has begun installation of key equipment for its newest sterile fill-finish facility on the company’s Bedford, NH campus. Twin lyophilizers and a state-of-the-art large-scale isolator….
Medigene AG Expands Patent Portfolio With Patent Grant for its Targeted T Cell Receptor
Medigene AG recently announced it has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1….
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles With siRNA Targeting p65 Protein in Treatment of Cancer & Inflammation
Altamira Therapeutics Ltd. recently announced it has filed a provisional patent application with the United States Patent Office (USPTO) which covers nanoparticles comprising the….
Adare Expands Global High Potency Handling & Packaging Capabilities
Adare Pharma Solutions, a global technology-driven CDMO specializing in oral dosage forms, recently announced expansions of its high potency handling capabilities in the….